Apellis Pharmaceuticals
APLS
APLS was delisted on the 13th of May, 2026.
46 hedge funds and large institutions have $340M invested in Apellis Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 46 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
31.29% more ownership
Funds ownership: 0% → 31.29% (+31%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$55.5M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$25.8M |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
+$21.5M |
| 4 |
HIM
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
|
+$21M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
+$16.8M |
Top Sellers
APLS Hedge Fund Activity: Q4 2017 in Review
46 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q4 2017, worth a combined $340M.
Buyers outnumbered sellers: 46 funds opened new APLS positions and 0 closed out — a net gain of 46 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $55.5M.
- 46 institutional investors held Apellis Pharmaceuticals (APLS) as of Q4 2017, up from 0 in Q3 2017.
- Funds reported $340M of Apellis Pharmaceuticals stock for Q4 2017.
- 46 funds opened new Apellis Pharmaceuticals positions in Q4 2017 and 0 closed out, a net change of +46 holders.
- The largest Apellis Pharmaceuticals buyer in Q4 2017 was Cormorant Asset Management, an estimated $55.5M added.
Based on aggregated 13F filings for Q4 2017.